0001193125-22-188992.txt : 20220707 0001193125-22-188992.hdr.sgml : 20220707 20220707070603 ACCESSION NUMBER: 0001193125-22-188992 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220705 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20220707 DATE AS OF CHANGE: 20220707 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 221070630 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d355522d8k.htm 8-K 8-K
false 0001840574 0001840574 2022-07-05 2022-07-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 5, 2022

 

 

Verve Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40489   82-4800132
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

500 Technology Square, Suite 901

Cambridge, Massachusetts

  02139
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 603-0070

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.001 par value per share   VERV   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Item 1.01

Entry Into a Material Definitive Agreement.

On July 5, 2022, Verve Therapeutics, Inc. (“Verve”), entered into an Amended and Restated Collaboration and License Agreement (the “Amendment”) with Beam Therapeutics Inc. (“Beam”), which amended the Collaboration and License Agreement entered into between Verve and Beam on April 3, 2019 (the “Original Agreement”, and as amended by the Amendment, the “Amended Agreement”). The Original Agreement provided Verve with an exclusive, worldwide, sublicensable license under certain of Beam’s base editing, gene editing, and delivery technologies for human therapeutic applications against four liver-mediated, cardiovascular disease targets, including PCSK9 and ANGPTL3, and two undisclosed gene targets (the “Undisclosed Genes”).

Pursuant to the Amendment, Beam granted Verve an exclusive, worldwide, sublicensable license under certain of Beam’s base editing technology to develop and commercialize products directed towards an additional liver-mediated, cardiovascular disease target. Verve will be responsible for the development and commercialization of products targeting such gene, subject to Beam’s opt-in right. Following the final dosing of a patient in a Phase 1 clinical trial of a licensed product for such gene, Beam has the right to opt-in to share 35% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share 35% of the profits and expenses of commercializing such licensed product worldwide. If Beam does not elect to opt-in, Beam would be entitled to receive milestones and royalties on the same basis as other collaboration products as provided in the Original Agreement.

In exchange, Verve granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under Verve’s intellectual property, including under Verve’s GalNAc-LNP delivery technology, relating to a preclinical program developed by Verve.

In addition, the Amended Agreement:

 

   

clarifies intellectual property rights with respect to Verve’s GalNAc-LNP delivery technology;

 

   

grants Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to Verve’s GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe Verve a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology;

 

   

terminates Verve’s rights and economic obligations under the Original Agreement with respect to the Undisclosed Genes, allowing Verve and Beam to independently develop and commercialize products directed to such gene targets; and

 

   

concludes other licenses that applied under the Original Agreement with respect to delivery and other technologies developed by the parties for the development and commercialization of base editor products.

The Amendment also contains representations and warranties, covenants, and other negotiated provisions, including confidentiality obligations, customary for transactions of this nature.

The foregoing descriptions of the terms of the Amended Agreement is qualified in its entirety by reference to the full text of the Amended Agreement, a copy of which Verve intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2022.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

VERVE THERAPEUTICS, INC.

Date: July 7, 2022

   

By:

 

/s/ Andrew Ashe

     

Name: Andrew Ashe

     

Title: President and Chief Operating Officer

EX-101.SCH 2 verv-20220705.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 verv-20220705_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 verv-20220705_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jul. 05, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001840574
Document Type 8-K
Document Period End Date Jul. 05, 2022
Entity Registrant Name Verve Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40489
Entity Tax Identification Number 82-4800132
Entity Address, Address Line One 500 Technology Square
Entity Address, Address Line Two Suite 901
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 603-0070
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, $0.001 par value per share
Trading Symbol VERV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d355522d8k_htm.xml IDEA: XBRL DOCUMENT 0001840574 2022-07-05 2022-07-05 false 0001840574 8-K 2022-07-05 Verve Therapeutics, Inc. DE 001-40489 82-4800132 500 Technology Square Suite 901 Cambridge MA 02139 (617) 603-0070 false false false false Common stock, $0.001 par value per share VERV NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d355522d8k.htm verv-20220705.xsd verv-20220705_lab.xml verv-20220705_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d355522d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d355522d8k.htm" ] }, "labelLink": { "local": [ "verv-20220705_lab.xml" ] }, "presentationLink": { "local": [ "verv-20220705_pre.xml" ] }, "schema": { "local": [ "verv-20220705.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "verv", "nsuri": "http://www.vervetx.com/20220705", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d355522d8k.htm", "contextRef": "duration_2022-07-05_to_2022-07-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d355522d8k.htm", "contextRef": "duration_2022-07-05_to_2022-07-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-22-188992-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-188992-xbrl.zip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